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Background: Bipolar disorder (BD) is a common mental disorder, subdivided into BD-I and BD-II.
Currently, few biomarkers differentiate BD-I from BD-II. However, it is suggested that peripheral blood
mononuclear cell (PBMC) mRNA levels of p11 and positron emission tomography (PET) might be
potential biomarkers for BD.
Methods: Healthy controls (HCs), BD-I, and BD-II patients in remission (n ¼ 20 in each group) underwent
a resting PET study with the radiotracer [18F]-2-deoxy-2-fluoro-D-glucose (18F-FDG). PBMC p11 mRNA
levels were determined by quantitative real-time PCR.
Results: Comparing BD patients to HCs, normalized glucose metabolism (NGM) was higher in the
hippocampus, parahippocampus, and amygdala, but lower in the anterior cingulate cortex (aCC), medial
prefrontal cortex (mPFC), dorsolateral prefrontal cortex (dlPFC), insula and thalamus. Compared to BD-II,
BD-I had hypometabolism of glucose in the aCC, bilateral middle and inferior gyrus, insula and striatum,
and hypermetabolism of glucose in the left parahippocampus. PBMC p11 mRNA was over-expressed in
both BD-I and BD-II, although there was no significant difference in its expression levels between BD-I
and B-II patients. Further, there were significant positive correlations between PBMC p11 mRNA and
NGM in the mPFC, aCC, left insula, bilateral orbitofrontal cortex (OFC), and left middle, inferior and
superior temporal gyri. Also, PBMC p11 mRNA was positively correlated to the number of depressive
episodes in BD patients, especially in BD-I patients.
Discussion: This study demonstrates that PBMC p11 mRNA expression is associated with neural activation
in the brain of BD patients and warrants a larger translational study to determine its clinical utility.
Published by Elsevier Ltd.
1. Introduction
BD is a complex, chronic psychiatric condition characterized by
recurring episodes of depression and mania or hypomania
(Michalak et al., 2008). It is subdivided into BD-I and BD-II, based on
the nature and severity of the mood episodes experienced. For
a diagnosis of BD-I, patientsmust have one ormoremanic episodes,
while a depressive or hypomanic episode is not required. For BD-II
diagnosis, patients must have one or more major depressive
episodes and no manic episodes, but may have one or more
hypomanic episodes. BD-II is sometimes difficult to distinguish
from BD-I clinically since the hypomanic episodes may simply
appear as a period of high productivity, and ‘social or occupational
impairment’ is hard to define under certain circumstances
(Salvadore et al., 2008). Furthermore, lacking objective criteria, the
diagnosis of BD is based on a subjective description by the patient
and a subjective observation by the psychiatrist. Although there
have been efforts to develop a clinical strategy to diagnose BD,
there is still no objective biological assay for the diagnosis of BD or
for the differentiation of BD-I from BD-II. The lack of quantitative
objective measures of BD is one reason that the causative factors of
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BD remain obscure. As it is believed that genetic factors and vari-
ability in neuronal activity contribute substantially to the likelihood
of developing BD (Craddock et al., 2005), we investigated the
correlation between PBMC p11 mRNA levels using real-time PCR
and neuronal activity using PET with 18F-FDG, in a group of BD
patients in remission. Previously, we found that p11 mRNA was
over-expressed in the PBMCs of patients with BD compared to
normal controls. P11, also known as S100A10, is a protein encoded
by the S100A10 gene in humans. It is a member of the S100 family
of proteins containing two EF-hand calcium-binding motifs, and is
localized in the cytoplasm and/or nucleus in a wide range of cells
(Manev and Manev, 2006). P11 regulates a number of cellular
processes such as cell cycle progression and differentiation. It is
implicated in exocytosis and endocytosis by reorganization of
F-actin (Gerke and Weber, 1985), as well as in the transport of the
5-HT1B receptor from the cytoplasm to the membrane
(Svenningsson et al., 2006). An association between p11 and
depression was found in a p11 knock-out study in mice and in
a post-mortem study in depressed patients (Anisman et al., 2008;
Svenningsson et al., 2006). Stress-induced changes in p11 expres-
sion most likely result from the activation of the hypothalamus-
pituitary-adrenal (HPA) axis (Anisman et al., 2008; Zhang et al.,
2008), indicating that there may be relationships between
peripheral p11 mRNA levels and CNS activity.
Using PET, recent studies found that BD patients have abnormal
neural activity in the limbic-thalamic-cortical circuit (Salvadore
et al., 2008). For example, medication-free depressed outpatients
with bipolar disorder had decreased metabolism in prefrontal,
anterior cingulate, insula, and ventral striatal areas (Brooks et al.,
2009). BD patients in remission have increased neuronal activity
in several limbic areas, such as hippocampus, parahippocampus
and amygdala (Drevets et al., 2008). Visualization of the resting
glucose metabolism in part of the prefrontal cortex (PFC), aCC,
insula, and striatum can be used to distinguish subtypes of mood
disorders (Brooks et al., 2009; Hosokawa et al., 2009).
Previous studies have reported that p11, a calcium binding
protein, is associated with both depression (Svenningsson et al.,
2006) and PTSD (Zhang et al., 2008). In the brain of patients, p11
mRNA was down-regulated in depression but up-regulated in
PTSD. Although there is a large number of calcium binding proteins,
p11 is the only one associated with depression and PTSD. These
results led us to hypothesize that p11 might be a potential
biomarker for BD. P11 regulates a number of cellular processes such
as cell cycle progression and differentiation, is implicated in
exocytosis and endocytosis by reorganization of F-actin, and
interacted with and transported the 5-HT1B receptor from the
cytoplasm to the membrane (Svenningsson et al., 2006). This
suggests that p11’s regulation of the 5-HT1B receptor is critical to
mental status. P11 knock-out mice showed behavioral changes,
which were similar to those of depression, and responded more
poorly to antidepressant medication than wild type mice because
of dysregulation of 5-HT1B receptor trafficking (Svenningsson et al.,
2006). Antidepressant medication increased expression levels of
p11 and reversed the depressive behavior (Svenningsson et al.,
2006). Although PET provides direct evidence of changes in
glucose metabolism, which may be used as a biomarker for BD
diagnosis, the expense and radiation exposure limit its utility.
Therefore, a blood biomarker for BD-I and BD-II, such as PBMC p11,
may complement the PET strategy in routine clinical practice since
analysis for mRNA markers in PBMCs is much less expensive than
PET, and carries no risk of radiation exposure. The goal of the
present study was to examine the hypothesis that PBMC p11 mRNA
levels can serve as an adjunctive biomarker for BD and are corre-
lated with neuronal activity, possibly indicating a role for p11 in the
pathophysiology of BD.
2. Methods and material
2.1. Ethics statement
The study was performed in accordance with the Declaration of
Helsinki and was approved by the Ethics Review Committee of the
Taipei Veterans General Hospital. The study was described
comprehensively to all subjects prior to their enrollment and all
participants signed a written informed consent (registration
number: R000003878; trial ID: UMIN000003199).
2.1.1. Subjects
The study subjects were outpatients of the Taipei Veterans
General Hospital from 2007 February to 2010 May. The diagnoses
were established by clinical history and by administration of the
Mini International Neuropsychiatric Interview (MINI) as found in
the Diagnostic and Statistical Manual of the American Psychiatric
Association (4th Edition, 1994). Patients were recruited for the
study only if they were 21e65 years of age, had no alcohol or
substance abuse history, no major physical or neurological illness,
and no comorbidity with schizophrenia, obsessive-compulsive
spectrum disorders, or post-traumatic stress disorder. They
received a range of medication based on their clinical presentation
and clinician’s judgment. To minimize heterogeneity, all partici-
pants were in the remission stage of BD (Hosokawa et al., 2009). A
patient was considered to be in remission when, for at least 2
weeks, both the 17-itemHamilton Depression Rating Scales (HDRS-
17) score was 9 or less and the Young Mania Rating Scale (YMRS)
score was 7 or less (Hirschfeld et al., 2007; Zimmerman et al.,
2004). After MINI screening, a group of healthy controls (n ¼ 20)
also participated in the study for the 18F-FDG PET comparisons.
Those with a family history of an axis I disorder including, schizo-
phrenia or major depression, in first degree relatives were
excluded.
2.2. PET study: imaging acquisition and analysis
All 40 patients and 20 healthy subjects received PET scans.
Patients fasted for at least 4 h before the PETexamination. PET scans
of glucose utilizationwere acquired on a PET/CT scanner (Discovery
VCT; GE Healthcare, USA) with a 3D brain mode. PET images were
acquired in 45 min after an intravenous injection of 370 MBq FDG.
In the combined PET/CT imaging, the standard PET transmission
scan is replaced by a low-dose CT scan. Then a CT-based attenuation
correction is given. PET images were scanned in the resting state
with eyes covered with a mask. The brain acquisition time was
15 min. The system produces 47 consecutive slices over an axial
length of 15.7 cmwith a slice thickness of 3.75 mm and a transaxial
FOV of 70 cm. PET images were reconstructed in a 128 128matrix
using CT for attenuation correction with an ordered-subset
expectation maximization iterative reconstruction algorithm (6
iterations and 14 subsets). Then the axial images were realigned to
yield sagittal and coronal images.
2.3. PBMC p11 mRNA assay
The PBMC study involved 52 subjects, including patients with
BD-I (n ¼ 18), BD-II (n ¼ 20), and normal controls (n ¼ 14) from the
Department of Psychiatry, Taipei Veterans General Hospital,
Taiwan. Heparinized and unheparinized blood samples (10 mL
each) were collected by venipuncture in vacutainer tubes. PBMCs
were separated by centrifugation on a Ficoll-Hypaque (Invitrogen)
density gradient. The blood samples were stored at 80 C. RNA
was extracted from blood lysates using a PAXgen blood RNA vali-
dation Kit (PreAnalytiX, Qiagen, Valencia, CA). cDNAwas generated
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from 3 mg of total RNA using Superscript III RT (reverse transcrip-
tase) and oligo (dT) primers (Invitrogen). Real-time PCR was per-
formed on the generated cDNA product in the IQ5 sequence
detection system using SYBR Green (Bio-Rad). The following
sequences were used for human p11 mRNA analyses: forward
50AAATTCGCTGGGGATAAAGG-30 and reverse 50AGCCCACTTTG
CCATCTCTA-30primers. b-actin mRNA levels were used as an
internal control for normalizing p11 mRNA levels in control and
experimental samples. The sequences for b-actin primers were 50-
ACCTGTACGCCAACACAGTG-30 and 50-ACACGGAGTACTTGCGCTCA-
30 (Applied Biosystems). Dilution curves confirmed the linear
dependence of the threshold cycle number on the concentration of
template RNAs. Relative quantitation of p11 mRNA in control and
experimental samples was obtained using the standard curve
method.
2.4. Statistical analysis
PET data were analyzed using the Statistical Parametric
Mapping, version 2 (SPM2; Wellcome Department of Cognitive
Neurology, Institute of Neurology, University College London,
London, England) implemented in Matlab 7.0 (The Mathworks
Inc., Sherborn, MA, USA). First, an 18F-FDG template was created
for all subjects including all BD patients and HCs (Gispert et al.,
2003). Then, each subject’s images were normalized to the 18F-
FDG template and smoothed with a 3D Gaussian kernel
(FWHM ¼ 12 mm). The overall grand mean from PET scans was
centered and normalized to 100, and global variance across scans
was removed by analysis of covariance (ANCOVA) (Friston et al.,
1990). To assess potential group differences of normalized brain
glucose uptake, an ANCOVA with age, gender (Willis et al., 2002)
and global gray matter values as covariates of no interest was
used for between-group comparisons (BD-I vs. BD-II). The
significance thresholds were set at p < .05 uncorrected at the
voxel level, followed by a cluster-level analysis with a corrected
p < .05. In addition, voxel-based partial correlations were per-
formed for investigating the association between 18F-FDG uptake
and PBMC p11 mRNA levels after accounting for age, gender and
total gray matter counts. Since the brain regions selected for
study were those known to be involved in the neural system
underlying BD e PFC, thalamus, aCC, insula, and striatum e the
identified brain regions within a priori areas were further
examined by Small Volume Correction (SVC) with an anatomi-
cally defined regional mask in the relevant gray matter area
(Friston, 1997). Those brain regions passing through an SVC-
corrected p-value <.05 were considered significant.
Table 1
Demographic data of BD-I and BD-II patients.
BD-I
n ¼ 20
BD-II
n ¼ 20
Mean/n SD/% Mean/n SD/%
Male, n (%) 10 50 6 29
Female, n (%) 10 50 14 71
Age (yrs) 43.9 2.6 42.9 2.8
Age at onset (yrs) 31.5 2.4 31.3 2.4
Years of duration (yrs) 12.7 2.7 11.5 1.5
Number of depressive episodes 3.9 3.7 6.4 5.1
Medication
Valproicacid (mg/day) 798.1 238.1 768.1 248.6
Quetiapine (mg/day) 245.6 161.6 213.3 83.3
Lamotrigene (mg/day) 115.0 65.8 137.4 54.0
Fig. 1. Normalized glucose metabolism in patients with BD-I and BD-II and in HCs under a corrected p < .05, after controlling for age and sex. (a) Glucose metabolism in
hippocampus and amygdala was significantly higher in BD patients as compared to controls; and significantly lower in aCC, mPFC, dlPFC, insula and thalami of BD patients
compared to HCs. (b) There were significant differences in glucose metabolism between BD-I and BD-II patients. BD-I patients had lower glucose metabolism in PFC, aCC, striatum
and bilateral insula (left panel), while BD-II patients demonstrated hypermetabolism of glucose in left parahippocampus/fusiform gyrus (right panel).
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All PBMC p11 mRNA levels are presented as mean  S.D. One-
way ANOVAs were used to evaluate differences in PBMC p11
mRNA levels among groups of BD-I, BD-II and control subjects. The
correlation coefficients and p-values were calculated using the
GraphPad Prism (GraphPad Software, Inc. San Diego, CA).
SPSS 18.0 was used to perform linear regressive analysis to
measure the correlation between the number of depressive
episodes and PBMC p11 mRNA levels.
3. Results
In total, 40 right-handed patients (BD-I¼ 20, BD-II¼ 20) were in
remission and did not differ with respect to current age, age at
onset of BD, gender, duration of illness, or number of previous
depressive and manic episodes, and the dosage of medication the
patients took (Table 1). NGMwas significantly higher in BD patients
as compared to HCs in the hippocampus, parahippocampus, and
amygdala, and significantly lower in aCC, mPFC, dlPFC, insula and
thalamic regions (p < .05; Fig. 1a). As compared to BD-II patients,
BD-I patients had hypometabolism of glucose in the aCC, bilateral
middle and inferior gyrus, insula, and striatum and hypermetabo-
lism of glucose in the left parahippocampus (p < .05; Fig. 1b).
PBMC p11 mRNA levels were measured by quantitative real-
time PCR (Fig. 2). P11 mRNA levels were significantly higher in
the PBMCs of both BD-I and BD-II patients compared to HCs
(***p < .001). However, PBMC p11 mRNA levels did not differ
between BD-I and BD-II patients (p > .05). P11 and normalized
glucose metabolism were significantly and positively correlated
in the PFC, aCC, left insula and left superior temporal gyrus
(Fig. 3).
Linear regressive analysis showed that, in subjects with BD,
PBMC p11mRNA level was positively correlatedwith the number of
depressive episodes (r ¼ 0.38, p < .05) (Table 2). After further
analysis, BD-I but not BD-II was found to be significantly correlated
to p11 expression in PBMC (Table 2).
4. Discussion
There are five major findings in this study. First, we found that
glucose metabolism levels in specific brain regions significantly
differed between BD patients (both BD-I and BD-II) and HC’s.
Second, we examined the correlation between p11 expression and
number of depressive episodes in BD, for both BD-I and BD-II. We
found that the PBMC p11 mRNA levels were positively correlated
with the number of depressive episodes in BD (Table 2). Further,
this positive correlation was obtained in BD-I, but not in BD-II
(Table 2). Third, we demonstrated that BD-I patients had signifi-
cantly different glucose metabolism levels in a number of brain
regions, as compared to BD-II patients. Fourth, we have shown that
p11 mRNAwas over-expressed in the PBMCs of both BD-I and BD-II
patients, as compared to controls, although there was no significant
difference in such expression levels between BD-I and BD-II. Finally,
we found a positive correlation between p11 mRNA in PBMCs and
glucose metabolism in the mPFC, aCC, left middle, left inferior, and
left superior temporal gyri, left insula, and bilateral OFC in BD
patients in remission.
The PBMC p11 mRNA over-expression might serve as
a compensatory mechanism for the decreased neuronal activity in
the brain of BD patients. Since the p11 protein is linked with the
transport of 5-HT1B receptors from the cytosol to the membrane
(Svenningsson et al., 2006) and has been implicated in the regu-
lation of mood and stress through the HPA axis, these results are
consistent with the hypothesis that the serotonergic system is
involved in the pathophysiology of BD.
Fig. 2. PBMC p11 mRNA levels in BD-I and BD-II patients compared to HCs. Quanti-
tative real-time PCR analysis revealed that p11 mRNA levels are significantly elevated
in PBMCs of both BD-I and BD-II patients compared to HCs. There is no significant
difference in PBMC p11 mRNA levels between BD-I and BD-II patients. ***p < .001.
Fig. 3. Correlation of PBMC p11 mRNA levels with normalized glucose metabolism in specific CNS regions. Correlation between p11 and normalized glucose metabolism in patients
with BD, under a cluster-level corrected p < .05 after controlling for age and sex. Glucose metabolism was positively correlated with PBMC p11 mRNA levels in aCC, mPFC, left
superior, middle and inferior temporal gyrii, left insula, and bilateral orbitofrontal cortex.
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The over-expression of PBMC p11 mRNA in remission patients
with BD may be caused by the dysregulation of certain brain
regions, particularly the hippocampus and amygdala, in response to
stress. A previous study on the stress-related regulation of p11
identified two specific glucocorticoid receptor response elements
(GRE) in the p11 promoter region (Zhang et al., 2008). Stress-
induced glucocorticoids activate glucocorticoid receptors (GR),
which translocate from the cytosol to the nuclear membrane. In the
nuclei, GR binds to the GRE in the p11 promoter and regulates p11
expression. This hypothesis was supported by our previous find-
ings, which showed that either treatment with a GR antagonist or
mutation of the GRE in the p11 promoter abolished glucocorticoid-
induced p11 over-expression (Zhang et al., 2008). Thus, stress-
induced p11 expression is mediated by GR and GRE in the p11
promoter, and this circuit may be involved in stress-related
diseases such as PTSD and affective disorders. Several brain
regions in which p11 is expressed (Sapolsky, 2000) are involved in
the stress response. For example, evidence from functional imaging
studies reveal that in anxiety disorders, brain activity in the
amygdala is enhanced abnormally when patients are exposed to
stressful situations (Drevets et al., 2002). Our findings of elevated
neural activity in the hippocampus and other closely related brain
regions, including the amygdala, could be a reflection of increased
activity along the HPA axis, which has been implicated in the
etiology of BD (Sassi et al., 2001). Even BD patients in remission
present abnormal activity in these stress-related brain regions.
In this study, we demonstrated that the PBMC p11 mRNA levels
were positively correlated with the number of depressive episodes
of BD-I but not BD-II. Thus, PBMC p11 mRNA level may serve as
a biomarker of BD-I. The effects of antidepressants on p11 expres-
sion levels in mice (Egeland et al., 2010) and glucose levels in
human have been reported (Videbech, 2000). In the present study,
we found there are no significant differences of medications
between BD-I and BD-II groups. That observation may rule out the
possibility that the differences of PBMC p11 mRNA levels between
BD-I and BD-II were resulted from the differences of the adminis-
tration of antidepressants. Although this needs to be validated
using a larger sample size, such a biomarker would facilitate deci-
sion making by clinicians diagnosing and establishing a therapeutic
strategy for BD.
To determine whether neural function can be a biomarker for
differentiation of BD-I and BD-II, we compared PET results of the
two groups. We found that, compared to BD-II patients, BD-I
patients in remission exhibited hypometabolism in the aCC, bilat-
eral middle and inferior gyrus, striatum and insula and hyperme-
tabolism in the hippocampus. This result is consistent with
previous studies investigating glucose metabolism in BD patients in
remission (Brooks et al., 2009) and with our own unpublished data.
In addition, PBMC p11 mRNA over expressionwas seen in both BD-I
and BD-II, indicating that it might serve as a compensatory mech-
anism for the alteration of neuronal activity in the brain of BD
patients.
The limitations of this study include limited sample size, lack of
quantitative (absolute cerebral metabolism) data, and heteroge-
neous medication regimens in patients. To the best of our knowl-
edge, however, this study is the first one to report a correlation
between PBMC p11 mRNA expression and neural activation in the
brain of BD patients. Our data warrant a comprehensive study to
determine whether PBMC p11 expression can serve as a biomarker
for BD diagnosis and whether PETcan be a tool for differentiation of
BD-I from BD-II.
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